These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23573612)

  • 1. [DCIS and HER2/neu].
    Tulusan AH
    Onkologie; 2002 Dec; 25 Suppl 5():11-2; discussion 13. PubMed ID: 23573612
    [No Abstract]   [Full Text] [Related]  

  • 2. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
    Eidtmann H
    Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in breast conservation therapy.
    Newman LA; Kuerer HM
    J Clin Oncol; 2005 Mar; 23(8):1685-97. PubMed ID: 15755977
    [No Abstract]   [Full Text] [Related]  

  • 4. [Radiotherapy of breast carcinoma. 2005 version].
    Organgruppe "Mammakarzinom" der DEGRO
    Strahlenther Onkol; 2006 Feb; 182 Suppl 1():4-28. PubMed ID: 16613299
    [No Abstract]   [Full Text] [Related]  

  • 5. Can some DCIS patients avoid adjuvant therapy? Still unknown.
    Schmidt C
    J Natl Cancer Inst; 2011 Apr; 103(7):530-1. PubMed ID: 21436062
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
    Gonzalez RJ; Buzdar AU; Fraser Symmans W; Yen TW; Broglio KR; Lucci A; Esteva FJ; Yin G; Kuerer HM
    Breast J; 2007; 13(1):72-5. PubMed ID: 17214797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab not for ductal carcinoma in situ?
    Nahleh Z; Namakydoust A; Bakkar R; Bishop J
    Anticancer Drugs; 2007 Nov; 18(10):1231-5. PubMed ID: 17893526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
    Hayes DF
    J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
    [No Abstract]   [Full Text] [Related]  

  • 10. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ductal carcinoma-in-situ.
    Wickerham DL
    J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapy decision - patient participation?]].
    Hilfrich J; Jänicke F
    Onkologie; 2002 Dec; 25 Suppl 5():25-7. PubMed ID: 23573618
    [No Abstract]   [Full Text] [Related]  

  • 14. Current concepts in the treatment of early stage breast cancer.
    Puckett C
    Del Med J; 1992 May; 64(5):313-9. PubMed ID: 1319354
    [No Abstract]   [Full Text] [Related]  

  • 15. [Does molecular biology play any role in ductal carcinoma in situ?].
    Sakr RA
    Gynecol Obstet Fertil; 2013 Jan; 41(1):45-53. PubMed ID: 23286959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
    Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab (herceptin) for early-stage breast cancer.
    Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy concept: herceptin in combination with arimidex].
    von Minckwitz G
    Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma
    Visser LL; Elshof LE; Schaapveld M; van de Vijver K; Groen EJ; Almekinders MM; Bierman C; van Leeuwen FE; Rutgers EJ; Schmidt MK; Lips EH; Wesseling J
    Clin Cancer Res; 2018 Aug; 24(15):3593-3601. PubMed ID: 29685879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.